Is BridgeBio Pharma Inc. (BBIO) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned BridgeBio Pharma, Inc. (NASDAQ: BBIO), and shared their insights on the company. BridgeBio Pharma, Inc. is a Palo Alto, California-based biotechnology company that currently has an $8.3 billion market capitalization. Since the beginning of the year, BBIO delivered a -20.69% return, while its 12-month gains are up by 94.68%. As of April 29, 2021, the stock closed at $55.27 per share.
Is UnitedHealth Group Inc. (UNH) A Good Investment Choice?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned UnitedHealth Group Incorporated (NYSE: UNH), and shared their insights on the company. UnitedHealth Group Incorporated is a Minnetonka, Minnesota-based managed care company that currently has a $379 billion market capitalization. Since the beginning of the year, UNH delivered a 14.51% return, extending its 12-month gains to 41.14%. As of April 29, 2021, the stock closed at $401.55 per share.
Is Pacific Biosciences of California (PACB) A Good Investment Choice?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned Pacific Biosciences of California, Inc. (NASDAQ: PACB), and shared their insights on the company. Pacific Biosciences of California, Inc. is a Menlo Park, California-based biotechnology company that currently has a $6.2 billion market capitalization. Since the beginning of the year, PACB delivered a 25.56% return, impressively extending its 12-month gains to 885.48%. As of April 28,
Should You Retain Your Arrowhead Pharmaceuticals (ARWR) Position?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), and shared their insights on the company. Arrowhead Pharmaceuticals, Inc. is a Pasadena, California-based biopharmaceutical company that currently has a $7.9 billion market capitalization. Since the beginning of the year, ARWR delivered a 0.36% return, while its 12-month gains are up by 136.52%. As of April 29, 2021, the stock closed at $7
Here’s Why Baron Health Care Fund Became Bullish in Cryoport Inc. (CYRX)
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here. A return of 0.58% was delivered by the fund’s institutional shares for the Q1 of 2021, below both its S&P 500 and Russell 3000 Health Care benchmarks that delivered a 6.17% and 2.14% returns respectively for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Baron Health Care Fund, in their Q1 2021 investor letter, mentioned Cryoport, Inc. (NASDAQ: CYRX), and shared their insights on the company. Cryoport, Inc. is a Brentwood, Tennessee-based cold chain logistics solutions provider that currently has a $2.5 billion market capitalization. Since the beginning of the year, CYRX delivered a 27.48% return, extending its 12-month gains to 210.43%. As of April 29, 2021, the stock closed at $55.94 per shar